What is the recommended diagnostic workup for suspected hypophosphatasia in a patient presenting with bone pain, fractures, premature loss of primary teeth, or unexplained musculoskeletal symptoms (including newborns or infants)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnostic Workup for Suspected Hypophosphatasia

When hypophosphatasia is suspected based on bone pain, fractures, premature tooth loss, or unexplained musculoskeletal symptoms, immediately measure serum alkaline phosphatase (ALP), serum pyridoxal 5'-phosphate (vitamin B6), urinary phosphoethanolamine, and proceed with ALPL gene testing to confirm the diagnosis. 1

Initial Laboratory Testing

The diagnostic workup should prioritize the following tests in order:

  • Serum alkaline phosphatase (ALP): Persistently low ALP (on majority of measurements) is the key biochemical hallmark that warrants full hypophosphatasia workup 1, 2. Markedly reduced serum ALP activity is the defining feature of this condition 3, 4.

  • Serum pyridoxal 5'-phosphate (PLP/vitamin B6): High serum concentrations represent a sensitive and specific biochemical marker for hypophosphatasia 2. This substrate accumulates due to TNSALP enzyme deficiency 5.

  • Urinary phosphoethanolamine (PEA): Elevated levels support the diagnosis, though this marker is less reliable than PLP 6, 2. Plasma ALP and urinary phosphoethanolamine are specifically recommended for childhood-type hypophosphatasia 6.

  • Serum PTH and 25(OH) vitamin D: These should be checked to exclude other metabolic bone disorders in the differential diagnosis 1.

Age-Specific Clinical Features to Assess

Newborns and Infants (Perinatal/Infantile Forms)

  • Severe undermineralization and bone deformity on radiographs 6
  • Respiratory complications and premature craniosynostosis 3
  • Widespread demineralization and rachitic changes in metaphyses 3
  • Hypercalcemia and hyperphosphataemia due to blocked mineral entry into skeleton 2
  • Pyridoxine-dependent seizures from vitamin B6 deficiency 5, 2

Children (Childhood Type)

  • Premature loss of primary teeth (fully rooted teeth exfoliating early) 6, 3
  • Rachitic bone changes with fractures 6
  • Skeletal deformities, short stature, and waddling gait 3
  • Undermineralization of bones on imaging 6

Adults

  • Stress fractures and recurrent fractures 1, 3
  • Skeletal pain and thigh pain 3, 7
  • Chondrocalcinosis and calcific periarthritis 7, 2
  • Dental problems including severe caries 3
  • Marked osteoarthropathy 3

Genetic Confirmation

  • ALPL gene sequencing: Identifies TNSALP mutations and confirms molecular diagnosis 4, 2. Approximately 95% of mutations are detected in severe (perinatal and infantile) forms 3. Around 300 predominantly missense ALPL mutations have been identified 2.

  • Gene analysis showing a pathogenic variant in ALPL confirms the diagnosis, though a substantial proportion of patients show normal results after sequencing ALPL exons 7.

Radiographic Evaluation

  • Obtain skeletal radiographs to assess for characteristic findings including undermineralization, fractures, and rachitic changes 6, 3.

  • In severe pediatric cases, pathognomonic radiographic changes aid diagnosis, showing marked bone hypomineralization 7, 2.

Critical Differential Diagnosis Considerations

The differential must exclude:

  • X-linked hypophosphatemia: Presents with hypophosphatemia but elevated (not low) ALP and elevated FGF23 1. This is the opposite ALP pattern from hypophosphatasia.

  • Osteogenesis imperfecta: May present with fractures and blue sclera, but typically has normal or elevated ALP 6, 8. Requires COL1A1/COL1A2 mutation testing if suspected 6.

  • Non-accidental injury: Must be considered in infants with unexplained fractures, though hypophosphatasia can be missed and incorrectly attributed to abuse 6.

Immediate Management Considerations

  • Discontinue antiresorptive therapy immediately if the patient is on bisphosphonates or denosumab, as these drugs are absolutely contraindicated in hypophosphatasia and may worsen symptoms 1.

  • Refer to an endocrinologist or metabolic bone disease specialist for confirmed or suspected hypophosphatasia, particularly if enzyme replacement therapy (asfotase alfa) is being considered 1, 2.

Common Pitfalls to Avoid

  • Do not dismiss low ALP as clinically insignificant—persistently low values demand investigation 1, 7.

  • Do not treat presumed "osteoporosis" with bisphosphonates without first excluding hypophosphatasia in patients with unexplained fractures and low ALP 1.

  • Blue sclera can occur normally in infants before 12 months of age, but beyond infancy requires pathologic investigation 6, 8.

  • In infants with fractures, do not rely solely on clinical examination—biochemical or DNA testing may be necessary to distinguish hypophosphatasia from other conditions 6.

References

Guideline

Management of Low Alkaline Phosphatase with Unexplained Fracture

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hypophosphatasia.

Orphanet journal of rare diseases, 2007

Guideline

Evaluation and Treatment Approach for Bluish Sclera

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

In a 32-year-old man with irritable bowel syndrome (diarrhea subtype) and a negative celiac disease work-up, what is the significance of a low-normal alkaline phosphatase (~45 U/L) and what should be the next step in management?
What is the appropriate management for a patient with a normal alkaline phosphatase level of 34?
What is the differential diagnosis and recommended evaluation for a 46-year-old male with persistently low alkaline phosphatase (26–33 U/L)?
In a 61-year-old male with decreasing alkaline phosphatase levels (39, 31, and 29 U/L) over the past nine months, what is the clinical significance and how should this be evaluated?
What are the implications and next steps for an 18-year-old male with elevated ALP (Alkaline Phosphatase) levels?
Does a decision‑making capacity evaluation require the patient to meet all four components—understanding, appreciation, reasoning, and communication—to be considered capacitated?
In a patient with right upper quadrant pain and normal ultrasound, normal HIDA scan, normal CT abdomen, and normal pelvic exam who has not yet tried a proton‑pump inhibitor or dicyclomine, what is the next appropriate step in management?
In a woman with atypical endometrial hyperplasia treated conservatively with a levonorgestrel‑releasing intrauterine device, how many years can the device be left in place if regression is confirmed?
Should I hold enoxaparin (Lovenox) in a patient with a platelet count of 59 ×10⁹/L that is decreasing after a recent cerebrovascular accident?
Can Celexa (citalopram) be prescribed at a 30 mg dose?
In a 60-year-old man with diabetes, hypertension, intermittent claudication and stable angina who is already receiving aspirin, rosuvastatin and sublingual nitroglycerin but continues to have exertional angina, with blood pressure 130/85 mm Hg and heart rate 86 beats/min, which additional medication is most appropriate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.